EBR Systems (ASX:EBR) said that its WiSE cardiac resynchronization therapy system was implanted in the first commercial patients in the US, following approval from the Food and Drug Administration, according to a Friday Australian bourse filing.
Reimbursement add-on payments for both inpatients and outpatients are expected to begin in October, the filing said.
The initiation of its limited market release is also expected in October, running into 2026, aimed at developing clinician advocacy and facilitating wider adoption.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。